Moreover, MIAT in hepatocellular carcinoma is linked to increased expression of immune checkpoint molecules (PD-1, PD-L1, CTLA4) and found in populations of immune cells associated with immune suppression. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.